Impact of blockers of AT1 receptors to angiotensin II on endothelium vasoregulating function in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001
Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Evaluation in administration of angiotensin II receptor antagonist Valsartan in the treatment of hypertension patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007
Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011
Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007
Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Source: Eur Respir J 2006; 28: 670 Year: 2006
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010